Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 8/20 | 0.67 |
| ▸ | PDPK1 | O15530 | 8/20 | 0.67 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.67 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.41 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.41 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12119839 | 0.90 | AURKA (0.54) | AURKAPDPK1AURKBEGLN2SUV39H2 | |
| SCHEMBL12119823 | 0.90 | AURKA (0.63) | AURKAPDPK1AURKBSUV39H2EIF2AK4 | |
| SCHEMBL16966477 | 0.89 | AURKA (0.51) | AURKAPDPK1AURKBEGLN2 | |
| SCHEMBL16977385 | 0.88 | PDPK1 (0.67) | AURKAPDPK1AURKBSUV39H2KDM4D | |
| SCHEMBL12119789 | 0.88 | PDPK1 (0.67) | AURKAPDPK1AURKBSUV39H2KDM4D | |
| SCHEMBL13354794 | 0.87 | AURKA (0.68) | AURKAPDPK1AURKBEIF2AK4 | |
| SCHEMBL12119825 | 0.85 | AURKA (0.58) | AURKAPDPK1AURKBSUV39H2EIF2AK4 | |
| SCHEMBL12119499 | 0.84 | PDPK1 (0.67) | AURKAPDPK1AURKBEGLN2SUV39H2 | |
| SCHEMBL12119114 | 0.84 | PDPK1 (0.67) | AURKAPDPK1AURKBEGLN2SUV39H2 | |
| SCHEMBL12119846 | 0.84 | AURKA (0.56) | AURKAPDPK1AURKBEGLN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | AURKA 298/4885PDPK1 12/4885AURKB 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.